A resolution designating the first full week in May as "Tardive Dyskinesia Awareness Week".

[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[S. Res. 477 Introduced in Senate (IS)]

<DOC>






119th CONGRESS
  1st Session
S. RES. 477

    Designating the first full week in May as ``Tardive Dyskinesia 
                           Awareness Week''.


_______________________________________________________________________


                   IN THE SENATE OF THE UNITED STATES

                            October 30, 2025

   Mr. Mullin (for himself and Mr. Padilla) submitted the following 
    resolution; which was referred to the Committee on the Judiciary

_______________________________________________________________________

                               RESOLUTION


 
    Designating the first full week in May as ``Tardive Dyskinesia 
                           Awareness Week''.

Whereas serious mental illnesses like bipolar disorder, major depressive 
        disorder, and schizophrenia often require treatment with antipsychotic 
        medications for effective management and antipsychotic prescribing rates 
        continue to rise;
Whereas, while prolonged antipsychotic use may be essential for the treatment of 
        certain conditions, it is associated with tardive dyskinesia (referred 
        to in this preamble as ``TD''), a condition marked by uncontrollable, 
        abnormal, and repetitive movements of the face, torso, limbs, or 
        extremities;
Whereas people at higher risk of TD include those older than 55 years of age, 
        Black individuals, women, individuals with mood or substance use 
        disorders, intellectual disabilities, or central nervous system 
        injuries, and those with high cumulative antipsychotic exposure;
Whereas approximately 60 percent of the estimated 800,000 adults living with TD 
        in the United States remain undiagnosed and even mild TD symptoms can be 
        stigmatizing and impair physical, social, and emotional well-being, 
        underscoring the urgency of early screening, detection, and 
        intervention;
Whereas the American Psychiatric Association recommends routine TD screening in 
        its clinical guidelines for antipsychotic treatment and individuals 
        treated with antipsychotics or experiencing abnormal movements should 
        consult their healthcare providers to assess TD risk, receive TD 
        screenings, and determine appropriate treatment together;
Whereas treatments approved for TD by the Food and Drug Administration can 
        provide options for symptom management and improved quality of life for 
        many individuals living with TD; and
Whereas the Senate can encourage TD screening education and awareness for health 
        care providers, patients, and care partners to help ensure patients 
        prescribed antipsychotics receive care and support that aligns with 
        clinical best practice, including regular TD screenings: Now, therefore, 
        be it
    Resolved, That the Senate--
            (1) designates the first full week in May as ``Tardive 
        Dyskinesia Awareness Week''; and
            (2) in recognition and support of Tardive Dyskinesia 
        Awareness Week--
                    (A) underscores the importance of early detection 
                and intervention to improve outcomes for individuals 
                living with mental health conditions and individuals 
                prescribed antipsychotics; and
                    (B) supports efforts to raise awareness about the 
                causes and symptoms of tardive dyskinesia and the 
                importance of routine tardive dyskinesia screening.
                                 <all>